Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT
Primary result · Non-remission (receiving ATD or TSH <0.1 mIU/L during last 12 months of intervention, or referral to ablative therapy)Result — go to the resultOR for non-remission 1.0 95% CI 0.7–1.5Authors' conclusion
In individuals with newly diagnosed Graves' hyperthyroidism, daily supplementation with selenium did not have any effects compared with placebo as add-on to standard antithyroid drugs. The GRASS trial findings do not support the use of selenium supplementation in Graves' hyperthyroidism.
Study context
- Population
- Individuals with newly diagnosed Graves' hyperthyroidismrecruited
- Participants
- 430 individuals
- Comparison
- Daily selenium 200 μg vs placebo
- Primary endpoint
- Non-remission: receiving antithyroid drug (ATD) or remaining hyperthyroid (TSH <0.1 mIU/L) during the last 12 months of the intervention, or referral to ablative therapy (RAI or surgery)
- Follow-up
- Last 12 months of the intervention period
Methodological detailsdouble-blind, placebo-controlled, multicentre, Recruitment Dec 7th 2012 to Dec 3rd 2018
- Double-blind
- Placebo-controlled
- Multicentre
- Recruitment Dec 7th 2012 to Dec 3rd 2018
Primary result
As reported in the abstract
Non-remission (receiving ATD or TSH <0.1 mIU/L during last 12 months of intervention, or referral to ablative therapy) · last 12 months of the 24-30-month intervention
OR for non-remission
1.0
95% CI 0.7–1.5
P = 0.98
Events by treatment group
Seleniumvs Placebo
OR for non-remission 1.0 (95% CI 0.7–1.5); P = 0.98
Further findings
Quality of life (QoL) (ThyPRO)
- No beneficial effect of selenium vs placebo on any ThyPRO scale
- QoL at end of study comparable to general population sample
TRAb levels · 18 months and end of study
- TRAb levels similar in the groups
Original publication
Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT. Eur Thyroid J. Published 12 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →